Aroa BiosurgeryASX:ARX +1.69%64 Days Payable is 116.60 as of Mar. 2026, which is 85% above its 10-year median of 62.92. GuruFocus rates ASX:ARX with a GF Score™ of 64/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 64.03% on this metric.
The historical rank and industry rank for Aroa Biosurgery's Days Payable or its related term are showing as below:
ASX:ARX'
s Days Payable Range Over the Past 10 Years
Min: 40.16 Med: 62.92 Max: 130.51
Current: 98.52
During the past 7 years, Aroa Biosurgery's highest Days Payable was 130.51. The lowest was 40.16. And the median was 62.92.
ASX:ARX's Days Payable is ranked better than 64.03% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs ASX:ARX: 98.52
Aroa Biosurgery's Days Payable
increased
from Mar. 2025 (61.87) to Mar. 2026 (116.60).
It may suggest that Aroa Biosurgerydelayed paying its suppliers.
Aroa Biosurgery Days Payable Related Terms
Aroa Biosurgery Days Payable Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Days Payable distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aroa Biosurgery's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a Days Payable of 116.60 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aroa Biosurgery and its competitors. This is 85% above median its historical median of 62.92. Over the past decade, Aroa Biosurgery's Days Payable has ranged from 40.16 to 130.51. According to the industry distribution chart, Aroa Biosurgery ranks #286 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 36%.
Is Aroa Biosurgery's Days Payable too high?
Aroa Biosurgery's current Days Payable of 116.60 is 85% above median its 10-year median of 62.92. Over the past 10 years, this metric has ranged from a low of 40.16 to a high of 130.51. The Medical Devices & Instruments industry median Days Payable is 68.07. Aroa Biosurgery's value of 116.60 is 71.3% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #286 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #286 out of 795 companies for Days Payable. This puts Aroa Biosurgery in the upper half of its industry. The industry median Days Payable is 68.07. Aroa Biosurgery's value of 116.60 is 71.3% above this benchmark. Historically, Aroa Biosurgery's own Days Payable has ranged from 40.16 to 130.51 over the past decade. While the company's 10-year median is 62.92 vs. the industry median of 68.07, Aroa Biosurgery has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current Days Payable of 116.60 is 71.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Days Payable is 116.60, which is 85% above median its own 10-year median of 62.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.60 — trading 25% below its estimated fair value. The current Days Payable is 116.60, which is 85% above median its 10-year median of 62.92 and 71.3% above the Medical Devices & Instruments industry median of 68.07. Aroa Biosurgery's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Days Payable is 116.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.60 is trading 25% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
Days Payable: 116.60 (85% above median its 10-year median of 62.92)
GF Value™: A$0.80 vs. price of A$0.60 (25% below fair value)
Industry Position: 71.3% above the Medical Devices & Instruments median (#286 of 795)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
64GF Score
Get the complete analysis for ASX:ARX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
